



SVANOVIR® PRV gB-Ab

Controlling Pseudorabies / Aujeszky's disease in non-vaccinated swine populations

SUMMARY | SVANOVIR® PRV gB-Ab assay is a robust ELISA for the detection of Pseudorabies / Aujeszky's disease in non-vaccinated swine populations. This high performing assay delivers accurate results essential for driving eradication procedures effectively and for certifying swine for import and export.



YOUR CHALLENGE is a persisting herpesvirus

The herpesvirus of Pseudorabies/Aujeszky's disease is an important pathogen in swine populations. The severity of the clinical manifestation in swine is age dependent, where severe disease with fatal outcome is mainly seen in young piglets. In adults the disease is fairly mild and after clinical recovery infected animals pose the risk for virus transmission.

YOUR GOAL is the reliable identification of latently infected animals

Pseudorabies/Aujeszky's disease is reported in domestic pigs and wild boar populations in various countries worldwide. The target of eradication programmes and of investigations for livestock movement is the identification of latently infected animals and their stamping out for interrupting the spread of the disease. In some countries Pseudorabies/Aujeszky's disease is controlled by vaccinating swine populations at risk of infection.



ASSAY OVERVIEW

SVANOVIR® PRV gB-Ab

Species	Porcine (incl. wild boars)		
Samples	Serum, plasma, whole blood (filter paper)*		
Type	Blocking ELISA based on full antigen, anti-gB(gII) monoclonal antibodies		
Article number	Plates	Tests	Samples
104905	2	192	184
104906	10	960	920


Tests: Number of tests **Samples:** Number of samples, wells for kit controls excluded.
* Extra protocol available on request

High performing test with high sensitivity and specificity figures

Validated for application in **domestic pigs and wild boars**

Standardised against the reference serum ADV-1

Field approved and used in eradication and control programmes in Europe



SVANOVIR® PRV gB-Ab provides precise results essential in effective surveillance, eradication programmes and livestock movement.

Easy and flexible protocol with ready to use reagents and alternative incubation time


Flexible format – for large scale testing as well as low throughput

Multilingual kit insert

Manufactured under strict **ISO 9001:2008 standardised procedures**

YOUR SUPPORT

From 9-16 CET call:

 **+46 18 65 49 15**

 **customer.service@svanova.com**

Boehringer Ingelheim Svanova
Box 1545
SE-751 45 Uppsala, Sweden

www.svanova.com

svanova 

PERFORMANCE CHARACTERISTICS SVANOVIR® PRV gB-Ab

The excellent performance of SVANOVIR® PRV gB-Ab has been demonstrated by testing a comprehensive number of serum samples originating from swine herds exposed to field virus. In this study a high agreement (99.6%) between SVANOVIR® PRV gB-Ab and Virus Neutralisation test (VNT) was seen. A specificity of 100% has been demonstrated in wild boar populations with historical freedom of disease (Surveillance Report, Sweden 2013).

		VNT		
		pos	neg	total
SVANOVIR® PRV gB-Ab	pos	675	3	678
	neg	0	684	684
total ^a		675	687	1362

Serum	Sensitivity	Specificity	Reference method
Negative herds n= 912 ^a	n.a.	100%	PRV free herds
Naturally infected, vaccinated, Non vaccinated herds n= 1362 ^a	100%	99.6%	VNT
Naturally infected, vaccinated, Non vaccinated herds n= 1000 ^b	99.6%	99.3%	Danish blocking ELISA*

J. Virol. Methods (1986). Samples originating from ^(a) Sweden, Yugoslavia, Germany, ^(b) Denmark

In a study performed by the National Reference Centre for Aujeszky's disease in Italy – on 46 well-defined samples - SVANOVIR® PRV gB-Ab showed 100% agreement with the reference method (in-house ELISA). In experimentally infected animals, SVANOVIR® PRV gB-Ab could detect antibodies as early as 10 days p.i. The excellent performance of the SVANOVIR® PRV gB-Ab will result in minimal analytical errors and will provide precise results in the identification of antibodies generated by field virus infection.

Reference: Surveillance of infectious diseases in animals and humans in Sweden 2013, National Veterinary Institute (SVA), Uppsala, Sweden. SVA:s rapportserie 28 ISSN 1654-7098.

Complementary product

SVANOVIR® PRV gE-Ab	A parallel test for DIVA vaccines enabling the detection of Pseudorabies/Aujeszky's disease in vaccinated swine populations
----------------------------	---